Finasteride
SIGMA/F1293 - ≥98% (HPLC), powder
Synonym: N-
CAS Number: 98319-26-7
Empirical Formula (Hill Notation): C23H36N2O2
Molecular Weight: 372.54
MDL Number: MFCD00869737
Linear Formula: C23H36N2O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C23H36N2O2/c1-21(2,3)2 |
| InChI key | DBEPLOCGEIEOCV-WSBQPABSSA |
| Quality Level | 100 ![]() |
| SMILES string | [H][C@@]12CC[C@@]3([H])[C |
| solubility | DMSO: soluble >20 mg/mL |
| storage temp. | room temp |
| Application: | Finasteride has been used: • as a component of L-15 media to investigate the effects of finasteride exposure on brain, liver and testis tissues • in culture medium to treat tumor cells in vitro • as a positive control to treat benign prostatic hyperplasia (BPH) • to examine its effect on structural and molecular biology on the ventral prostate of senile mice |
| Biochem/physiol Actions: | Finasteride can reduce serum and scalp dihydrotestosterone (DHT) by preventing the transformation of testosterone to DHT. It is usually used to manage benign prostate hyperplasia and pattern hair loss in male. Finasteride possesses androgen-distracting properties. |
| Biochem/physiol Actions: | Selective 5α-reductase inhibitor; antiandrogen. |
| Packaging: | 100 mg in glass bottle |
| Symbol | ![]() GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 - H360FD |
| Precautionary statements | P201 - P202 - P264 - P270 - P301 + P312 - P308 + P313 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 41116107 |



